Related Experiment Video

Updated: May 17, 2025

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
08:05

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Published on: December 9, 2022

3.9K

Local and Systemic Endothelial Damage in Patients with CEAP C2 Chronic Venous Insufficiency: Role of Mesoglycan

Angelo Santoliquido1,2, Claudia Carnuccio1, Luca Santoro1

  • 1Angiology and Noninvasive Vascular Diagnostics Unit, Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.

International Journal of Molecular Sciences
|May 14, 2025
PubMed

Insights

Mesoglycan treatment reduced inflammation and glycocalyx damage in chronic venous disease (CVD) patients. This glycosaminoglycan therapy shows promise for managing CVD by targeting key inflammatory markers.

Area of Science:

  • Vascular Biology
  • Pharmacology
  • Biochemistry

Background:

  • Chronic venous disease (CVD) is linked to matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) imbalance, venous remodeling, and inflammation.
  • Elevated MMP-2, MMP-9, and pro-inflammatory markers are observed in varicose veins, with syndecan-1 (SDC-1) alterations indicating glycocalyx damage.
  • Endothelial glycocalyx integrity is crucial for vascular health, and its damage is implicated in various vascular diseases.

Purpose of the Study:

  • To investigate inflammatory changes and glycocalyx damage in patients with chronic venous disease (CVD).
  • To evaluate the therapeutic efficacy of mesoglycan, a glycosaminoglycan, in managing CVD-related inflammation.

Main Methods:

  • A prospective study involving 23 patients with C2 CEAP (Clinical-Etiological-Anatomical-Pathological) classification of CVD.
  • Serum samples were analyzed for inflammatory markers (VCAM-1, MMP-2, MMP-9, SDC-1, IL-6, IL-8) before and after 90 days of mesoglycan treatment.
  • Patients received 50 mg of mesoglycan orally twice daily.

Main Results:

  • Significantly elevated levels of VCAM-1, MMP-2, MMP-9, SDC-1, IL-6, and IL-8 were detected in blood from varicose veins compared to systemic circulation.
  • Mesoglycan treatment resulted in a significant reduction in these inflammatory markers.
  • These findings suggest mesoglycan alleviates both local and systemic inflammation associated with CVD.

Conclusions:

  • Mesoglycan demonstrates a therapeutic role in reducing inflammation and potentially mitigating glycocalyx damage in CVD patients.
  • The study provides evidence for mesoglycan as a potential treatment strategy for managing chronic venous disease.
  • Further research into mesoglycan's mechanisms in CVD is warranted.
Keywords:
chronic venous diseaseglycocalyxmesoglycansyndecanssystemic inflammation

More Related Videos

In vivo Measurement of the Mouse Pulmonary Endothelial Surface Layer08:55

In vivo Measurement of the Mouse Pulmonary Endothelial Surface Layer

Published on: February 22, 2013

14.5K
Development of a Noninvasive, Laser-Assisted Experimental Model of Corneal Endothelial Cell Loss06:23

Development of a Noninvasive, Laser-Assisted Experimental Model of Corneal Endothelial Cell Loss

Published on: April 24, 2020

5.3K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
52
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
31
Vascular Spasm01:16

Vascular Spasm

The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
1.1K